TABLE 1

Summary of vitreous activities and characteristics

CategorySpecific activity*PVitreous proteinPVitreous activity§
Normal vs.0.06 ± 0.04 (4)6.40 ± 1.64 (4)0.39 ± 0.28
Diabetes0.42 ± 0.30 (64)0.018.16 ± 3.30 (48)0.083.41 ± 2.84
Female vs.0.40 ± 0.27 (31)7.97 ± 3.32 (24)3.16 ± 2.51
Male0.45 ± 0.34 (33)0.268.06 ± 3.02 (24)0.373.59 ± 3.02
    22–39 years0.57 ± 0.32 (10)5.73 ± 2.19 (5)3.25 ± 2.19
    40–49 years0.49 ± 0.31 (8)5.96 ± 3.13 (9)2.93 ± 2.41
    50–59 years0.31 ± 0.23 (19)9.19 ± 3.54 (14)2.82 ± 2.39
    60–69 years0.44 ± 0.36 (16)8.81 ± 2.12 (11)3.87 ± 3.31
    70–80 years0.41 ± 0.22 (10)0.259.32 ± 3.00 (9)0.053.83 ± 2.42
Hemorrhage (−) vs.0.45 ± 0.31 (20)8.47 ± 2.82 (8)3.82 ± 2.89
Hemorrhage (+)0.40 ± 0.30 (44)0.298.10 ± 3.43 (40)0.393.27 ± 2.81
PDR (−) vs.0.19 ± 0.07 (5)8.56 ± 2.53 (4)1.59 ± 0.76
PDR (+)0.44 ± 0.31 (59)0.048.12 ± 3.36 (44)0.403.55 ± 2.90
PDR (+) hemorrhage (−) vs.0.51 ± 0.30 (17)8.08 ± 3.04 (6)4.09 ± 2.86
PDR (+) hemorrhage (+)0.41 ± 0.31 (42)0.078.13 ± 3.41 (38)0.493.33 ± 2.87
  • Data are means ± SD or means ± SD (n) unless otherwise indicated.

  • *

    * Specific activity represents the percent contraction per ODU protein, normalized to the experimental FBS standard as described in Fig. 1.

  • Unpaired Student’s t tests were used to evaluate differences attributed to sample characteristics except age-related differences, which were evaluated using single-factor ANOVA. P values in bold were considered significant.

  • Vitreous protein is the vitreous sample protein concentration divided by the fractional percent vitreous as determined by fluorescein dilution.

  • §

    § Vitreous activity is the product of specific activity and vitreous protein.

  • Normal refers to vitreous samples removed from nondiabetic patients with vitreous opacities and without other retinal pathology.